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The development of patient-friendly alternatives to bone-graft procedures is the driving force23
for new frontiers in bone tissue engineering. Poly (DL-lactic-co-glycolic acid), (PLGA) and24
chitosan are well-studied and easy-to-process polymers from which scaffolds can be25
fabricated. In this study, a novel dual-application scaffold system was formulated from26
porous PLGA and protein-loaded PLGA/chitosan microspheres. Physicochemical and in vitro27
protein release attributes were established. The therapeutic relevance, cytocompatibility with28
primary human mesenchymal stem cells (hMSCs) and osteogenic properties were tested.29
There was a significant reduction in burst release from the composite PLGA/chitosan30
microspheres compared with PLGA alone. Scaffolds sintered from porous microspheres at31
37°C were significantly stronger than the PLGA control, with compressive strengths of 0.84632
± 0.272 MPa and 0.406 ± 0.265 MPa, respectively (p < 0.05). The formulation also sintered at33
37°C following injection through a needle, demonstrating its injectable potential. The34
scaffolds demonstrated cytocompatibility, with increased cell numbers observed over an 8-35
day study period. Von Kossa and immunostaining of the hMSC-scaffolds confirmed their36
osteogenic potential with the ability to sinter at 37°C in situ.37
Keywords: polymeric biomaterials, controlled delivery, poly (lactic-co-glycolic acid)38
(PLGA), microspheres, protein delivery, tissue engineering, mechanical properties,39
formulation.140
1Abbreviations
BMPs, bone morphogenetic proteins; BSA, bovine serum albumin; DCM, dichloromethane; DMSO, dimethyl
sulphoxide; ECM, extracellular matrix; FTIR, Fourier transform infrared; hMSC, primary human mesenchymal
stem cells; PBS, phosphate-buffered saline; PLGA, poly (lactic-co-glycolic acid); PVA, poly (vinyl alcohol);
SDS, sodium dodecyl sulphate; SEM, scanning electron microscopy, TPP, sodium tripolyphosphate; ToF-SIMS,
time of flight secondary ion mass spectroscopy.
31. Introduction41
There is an urgent need for alternative approaches for the regeneration of bone42
following fracture or orthopaedic damage in lieu of traditional methods, and these alternative43
approaches constitute an important tissue engineering application (Vo et al., 2012). The44
current ‘gold standard’ therapy is the bone graft procedure, which involves taking autologous45
bone, usually harvested from the iliac crest of the patient, and implanting it into their defect46
site (Martino et al., 2012; Amini et al., 2013). Alternatively, allograft bone from donors or47
cadavers can be extracted from the femoral heads or extremities of other long bones (Delloye48
et al., 2007). This implanted tissue acts as a scaffold for the existing bone tissue to infiltrate49
and deposit extracellular matrix (ECM), leading to the remodelling of the fractured bone50
(Bostrom and Mikos, 1997). Numerous drawbacks are associated with the above procedures,51
including the limited supply of autologous bone, complications at the donor site and high52
surgical costs (Martino et al., 2012). Furthermore, in large defects, resorption may occur53
before osteogenesis has been completed (Burg et al.,2000). Allograft bone usage is associated54
with incompatibility with the host, and the possible transmission of diseases and infections55
such as hepatitis and HIV ( Vo et al., 2012; Bostrom and Mikos, 1997; Chen et al., 2010;56
Puppi 2010). The risk of disease transmission from allograft bone can be minimised by57
processing or devitalization via freeze-drying or irradiation; however, this may reduce the58
osteoinductivity and mechanical strength (White et al., 2013; Hau et al., 2008; Nauth et al.,59
2011). Other options include the usage of bone morphogenetic proteins (BMPs), distraction60
osteogenesis and bone cement; however, these are also not ideal (Amini et al., 2013). The61
shortcomings in the current clinical options have led to concerted efforts in search of62
alternative strategies for the repair of bone.63
Poly (DL-lactic-co-glycolic acid) (PLGA) is a well-studied synthetic polymer used in64
bone tissue engineering. It has favourable properties such as biodegradability (Pan and Ding,65
42012), cytocompatibility, controllable mechanical properties (Bostrom and Mikos, 1997;66
Burg et al., 2000; Chen et al., 2010; Puppi et al., 2010) and it can be easily processed (Burg et67
al., 2000; Pan and Ding, 2012). Furthermore, PLGA has been approved by the FDA for use in68
certain clinical applications (Lu et al., 2009).69
The combination of porous and non-porous microspheres, which are able to sinter at70
body temperature, enables the introduction of porosity within injected scaffolds, hence,71
allowing proliferating cells access to nutrients [Qutachi et al., 2014; Boukari et al., 2015).72
Simultaneously, the delivery of growth factors such as BMPs to the growing cells is also73
facilitated. BMPs have been studied for their use in non-union bone defects, spinal fusion and74
open tibial fractures (Boukari et al., 2015; Whilte et al., 2013; Hau and Wang, 2008).75
Furthermore, it has been reported that one such BMP, BMP-2, is present during the initial76
phase of fracture repair, and during chondrogenesis and osteogenesis (Patel et al., 2008).77
Various strategies have been utilized for the sintering of microspheres into scaffolds.78
These include the incorporation of plasticizers in order to reduce polymer glass transition79
temperatures (Dhillon et al., 2011), the addition of organic solvents such as dichloromethane80
(Pan and Ding, 2012; Wang et al., 2010) and the application of heat (Delloye et al., 2007;81
Chen et al., 2010; Puppi et al, 2010). Although the use of high temperatures and organic82
solvents result in mechanically strong scaffolds, these conditions are not ideal for the body83
and so are not suitable for sintering in-situ. Therefore, a system capable of sintering at 37°C84
in situ would be extremely beneficial.85
Protein-loaded PLGA microspheres often exhibit an initial burst release (Boukari et al.,86
2015; Tao et al., 2014) which is not ideal for an intended controlled release of BMP-2 at a87
defect site. A number of strategies have been employed to control the release of proteins from88
PLGA microspheres. These include varying the polymer molecular weight (Boukari et al.,89
52015), the inclusion of additives such as poloxamer 188 (Paillard-Giteau et al., 2010) and the90
use of a PLGA-PEG-PLGA triblock polymer (White et al., 2013; Kirby et al., 2011).91
Chitosan is a natural polysaccharide derived from chitin and is popular in tissue92
engineering applications for a variety of reasons, which include its cytocompatibility and93
ability to promote cell adhesion (Amini et al., 2012). Chitosan microspheres show promise94
for use in the encapsulation of proteins and have previously been shown to retain the activity95
of a neural growth factor (Zeng et al., 2011). Moreover, due to its cationic nature and96
propensity to slow degradation, chitosan-based materials are able to sustain the release of97
growth factors (Qian and Zhang, 2013). Chitosan has been used in combination with PLGA98
in various forms, including by embedding PLGA microspheres into chitosan scaffolds (Kirby99
et al., 2011; Zeng et al., 2011; Di Martino et al., 2005; Qian, 2013). PLGA/chitosan100
microspheres can be formulated in a variety of ways. These include the use of supercritical101
fluid technology (Cassetari et al., 2011), the double emulsion method (Fu et al., 2012; Hu et102
al., 2008) the solvent evaporation technique (Jian et al., 2010), an electro-dropping layer-by-103
layer approach (Choi et al., 2013) and conjugation and adsorption methods (Chakravarthi and104
Robinson, 2011). Porous microspheres have also been treated with chitosan (Yue et al., 2015)105
(Chakravarthi and Robinson, 2011), whilst others have encapsulated protein-loaded chitosan106
microspheres into large porous PLGA microspheres (Tao et al., 2014).107
In a previous study, we reported the formulation of a novel PLGA scaffold delivery108
system based on porous and protein-loaded microspheres that sintered at 37°C (Boukari et al.,109
2015). There have been a number of reports utilising composites of PLGA/chitosan110
microspheres for use in bone tissue engineering (Casettari et al., 2011; Han et al., 2015;111
Pandey et al., 2013; Jiang et al., 2010; Choi et al., 2013; Chakravarthi and Robinson, 2011).112
In the present work, we report the development of a ‘dual-application’ PLGA/chitosan113
composite scaffold formulation which sinters at 37°C when injected through a hypodermic114
6needle as well as when implanted as a paste. Furthermore, we aimed to control the release115
kinetics of a model protein for BMP-2 (BMP-2 itself was not used due to the cost116
implications) from this system, via the inclusion of chitosan, and to investigate its117
cytocompatibility and osteoinductive capabilities on primary human mesenchymal stem cells118
(hMSCs).119
2. Materials and methods120
2.1 Materials121
PLGA (85:15, 53 kDa) was purchased from Evonik (Morris, NJ, USA). Chitosan, low122
molecular weight, ≥ 75% deacetylation; sodium tripolyphosphate (TPP); poly vinyl alcohol 123 
(PVA), 87–89% hydrolysed; phosphate buffered saline (PBS; 0.01 M phosphate buffer,124
0.0027 M potassium chloride and 0.137 M sodium chloride; pH 7.4) tablets; sodium125
hydroxide (NaOH) pellets; Triton X-100; goat serum; Hoechst 33258; sodium thiosulphate126
solution; silver nitrate solution; formalin 10% v/v and paraformaldehyde 10% v/v solutions127
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Glacial acetic acid was128
purchased from R&M Chemicals (Essex, UK). Dichloromethane (DCM), dimethyl sulfoxide129
(DMSO) and sodium dodecyl sulphate (SDS) were purchased from Fisher Scientific UK130
(Loughborough, UK). Bovine serum albumin (BSA) was purchased from Nacalai Tesque131
(Kyoto, Japan). A micro BCA protein assay kit was purchased from Thermo Fisher Scientific132
(Waltham, MA, USA). For stem cell culture, hMSCs, an MSCGM hMSC SingleQuot kit,133
trypsin/EDTA for MSC and HEPES buffered saline were purchased from Lonza (Basel,134
Switzerland). Presto Blue cell viability reagent was purchased from Gibco, Life Technologies135
(Carlsbad, CA, USA). For immunostaining, anti-osteocalcin polyclonal antibody was136
7purchased from Merck Millipore (Billerica, MA, USA) and alexa flour 488 goat anti-rabbit137
IgG was purchased from Invitrogen (Carlsbad, CA, USA).138
2.2 Formulation of PLGA microspheres139
Porous PLGA microspheres were prepared using the double emulsion solvent140
evaporation method as described in detail elsewhere (Qutachi et al., 2014; Boukari et al.,141
2015). Briefly, a 250-µl aliquot of PBS was added to a 20% w/v PLGA/DCM solution and142
homogenized at 9000 rpm using a Silverson L5M homogeniser (East Longmeadow, MA,143
USA). This was added to 200 ml of 0.3% w/v PVA solution and homogenized at 4000 rpm144
and then stirred at 300 rpm for 4 hours. The microspheres were washed with distilled water145
and then exposed to ethanolic-NaOH in order to enhance the surface porosity. They were146
then sieved (40 µm) and washed using distilled water. Non-porous microspheres were147
prepared in a similar way using 100 µl of 100 mg/ml BSA solution or 100 µl of distilled148
water, instead of 250 µl of PBS. BSA was chosen as a model protein as it is compatible with149
chitosan and has previously been used as a substitute for growth factors (Song et al., 2013;150
Yilgor et al., 2010; Yilgor et al.,2009).151
Non-porous PLGA/chitosan composite microspheres were prepared similarly;152
however, instead of using 200 ml of 0.3% w/v PVA solution, the aqueous phase comprised153
150 ml of 0.4% w/v PVA solution containing 0.05 g of TPP. The primary emulsion, in154
addition to 50 ml of 0.25% w/v chitosan solution in 2% v/v acetic acid, was added to the155
external aqueous phase simultaneously and homogenized. All microspheres were freeze-dried156
using a Thermo Fisher Scientific FR-Drying Digital Unit (Waltham, MA, USA) for 48 hours157
and stored at -20ºC until use.158
82.3 Scanning electron microscopy (SEM) and size analysis159
The freeze-dried samples were mounted onto aluminium stubs (Agar Scientific, UK)160
and gold-coated using a Balzers SCD030 gold sputter coater (Balzers Union Ltd.,161
Lichtenstein). The morphology and surface topography of the microspheres were observed162
using a Jeol 6060L SEM imaging system (Jeol Ltd., Hertfordshire, UK) at 10 kV. The163
particle size distribution and mean microsphere diameter were determined using a Coulter164
LS230 particle size analyser (Beckman, UK).165
2.4 Fourier transform infrared (FTIR) spectroscopy166
FTIR spectra of the microspheres and their constituents were obtained using a167
Spectrum RX 1 FTIR spectrophotometer (Perkin Elmer, Waltham, MA, USA). Samples were168
mixed with potassium bromide (KBr) and compressed using a 5-tonne force into disks; 256169
scans were acquired from 400 to 4000 cm-1.170
2.5 Preparation of 3D scaffolds171
PLGA and PLGA/chitosan composite scaffolds were previously prepared in our172
laboratories (Boukari et al., 2015). A 1:1 mass ratio of porous to non-porous microspheres173
was mixed in a weighing boat followed by mixing with PBS (pH 7.4) at a ratio of 0.25:1174
(PBS to microspheres) to form a paste. The paste was packed into a 6-mm diameter and 12-175
mm height polytetrafluorethylene (PTFE) mould using a spatula, and then stored in a sealed176
de-humidifying chamber at 37°C for 17 hours.177
178
2.6 Time of flight secondary ion mass spectrometry (ToF-SIMS)179
9The presence and distribution of the chitosan coating on the scaffold surfaces was180
assessed using a time of flight secondary ion mass spectrometer (ToF-SIMS IV, ION-TOF181
GmbH, Munster, Germany). Scaffolds were placed on the ToF-SIMS stage and secured with182
metal clips. A 25-keV Bi3+ primary ion source was used to scan a 256 × 256 pixel raster,183
while simultaneously not exceeding the limit of static, as described by Rafati et al., (2012).184
Surface charge due to the primary ion beam on the insulating sample surface was185
compensated using a flood gun generating low energy electrons (20 eV). Negative and186
positive polarity data for 500 × 500 µm areas were analysed using the SurfaceLab 6 software187
(IONTOF, Germany). PLGA was identified by the presence of C3H3O2- (m/z = 71) and188
C3H5O2- (m/z = 73) (Rafato et al., 2012). Diagnostic secondary ion peaks for chitosan were189
identified as CN- (m/z = 26) from the negative polarity data, in addition to CH4N+ (m/z = 30)190
and C4H5N2+ (m/z = 81) from the positive polarity data. For a semi-quantitative analysis, each191
area was split into four regions of interest, and the ion intensity data for these peaks of192
interest were exported and normalized to the total ion intensity.193
2.7 Encapsulation efficiency (%EE) of BSA within microspheres and scaffolds194
The %EE of BSA within the non-porous PLGA and PLGA/chitosan composite195
microspheres and scaffolds were determined by gently stirring 10 mg of the microspheres or196
one scaffold in 750 µl or 13 ml of DMSO, respectively, for 1 hour. This was followed by the197
addition of 2.15 ml or 37.27 ml of 0.02% w/v SDS in 0.2 M NaOH to the microspheres or198
scaffolds, respectively. The solution was left to stand at room temperature for 1 hour.199
Standard concentrations of BSA were calibrated with a BCA reagent so that the sample200
absorbance could be matched with standard concentrations on an Infinite 200 plate reader201
(Tecan, Switzerland) at 562 nm. The %EE of BSA within the microspheres and scaffolds was202
then calculated using Equation 1.203
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%EE = Actual mass of BSA in 10mg of microspheres OR 1 scaffoldTheoretical mass of BSA used for 10 mg of microspheres OR 1 scaffold × 100 (1)204
205
2.8 Release of BSA from microspheres and scaffolds206
Release studies of BSA from the PLGA and PLGA/chitosan composite microspheres207
were carried out by submerging 50 mg of microspheres in 1.5 ml of PBS in a micro-208
centrifuge tube. The tubes were incubated at 37°C. At predetermined time intervals, the PBS209
supernatant was removed and replaced with fresh buffer. Aliquots (150 µl) were withdrawn210
from the supernatant and assayed for the presence of BSA at 562 nm on the microplate reader211
using the BCA assay kit. BSA release from scaffolds was studied in 4 ml of PBS and assayed212
as described above.213
214
2.9 Preparation of 3D scaffolds post-injection215
Microsphere mixtures were prepared at a 1:1 ratio of porous to non-porous216
microspheres and an approximate BSA loading of 3 mg of BSA/g of mixture, as described in217
section 2.5. The mixture was suspended in PBS at a concentration of 50 mg of218
microspheres/ml, vortex-mixed briefly and then drawn into a 1-ml syringe (BD Fine) fitted219
with a 19-G needle (1.1 × 50 mm, BD fine, Franklin Lakes, NJ, USA). Finally, the contents220
of the syringe were injected into the PTFE scaffold mould.221
222
2.10 Compressive strength of scaffolds223
The compressive strength of the scaffolds was assessed using a TA.HD+ texture224
analyser (Stable Microsystems, UK) equipped with a 50-kg load cell at a speed of 0.04225
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mm/second over a contact area of approximately 28.75 mm2. Dry PLGA and PLGA/chitosan226
BSA-loaded scaffolds prepared as described in sections 2.5 and 2.9 were tested, and the227
compressive strength was determined as the stress at the maximum strain.228
229
2.11 Cell culture and seeding onto scaffolds230
Primary hMSCs were cultured in hMSC basal media supplemented with the contents231
of an MSCGM hMSC SingleQuot kit. The cells were maintained in a humidified tissue-232
culture incubator at 37°C in 5% CO2. The cytocompatibility test was carried out on BSA-free233
scaffolds. Scaffolds were prepared directly into a 24-well plate in a manner similar to that234
described in section 2.5. A 1:1 porous to non-porous microsphere mixture was UV sterilised235
for 80 minutes (Gould et al., 2013) and then transferred to the well. Basal growth medium236
was then added at a ratio of 0.25:1 (medium to microspheres). After 17 hours of sintering,237
each scaffold was seeded with 1 × 105 hMSCs and incubated for 2 hours, followed by the238
addition of 1 ml of media to each scaffold/well. The cell-seeded scaffolds were maintained at239
37°C with 5% CO2. For all cell experiments, either 5 replicates or 2 independent repeats each240
comprising at least 3 replicates was carried out.241
2.12 Cell viability assay242
Each scaffold was submerged in 1 ml of media and 111 µl of Presto Blue reagent and243
the cell viability was determined at day 1, 3, 6 and 8 post-seeding using the Presto Blue cell244
viability reagent. The well plate was protected from light and incubated at 37°C for 25245
minutes. Aliquots of 100 µl were withdrawn from each well in triplicate and the absorbance246
was read on an infinite 200 plate reader (Tecan, Switzerland) at excitation and emission247
wavelengths of 560 nm and 590 nm, respectively. The Presto Blue reagent was replaced with248
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fresh media and the scaffolds were placed back in the incubator. On day 8, after measuring249
the cell viability, the scaffolds were washed with PBS and the cells were fixed with 10% v/v250
buffered formalin solution for 20 minutes. Fixed hMSC-scaffold constructs were viewed251
under the SEM.252
2.13 Assessment of mineralization253
In order to determine the degree of mineralization on the scaffolds, the von Kossa254
assay was utilized. Cells were seeded onto scaffolds as described in section 2.11 and255
incubated in basal growth media for 21 days. On day 21, cells were fixed with 10% v/v256
buffered formalin for 20 minutes and thoroughly washed with PBS. A 450-µl aliquot of 1%257
w/v silver nitrate solution was added to each scaffold and incubated under a UV light source258
for 1 hour. The solution was then removed and the scaffolds were washed three times with259
deionized water. This was followed by treatment with sodium thiosulphate solution for 5260
minutes in order to remove any excess silver nitrate solution. The scaffolds were then washed261
with PBS prior to imaging under a dissection microscope (Leica, Germany).262
263
2.14 Osteocalcin immunostaining264
Cells were seeded onto scaffolds as described in section 2.11. The scaffolds were265
incubated in basal growth media for 21 days after which they were fixed using 10% v/v266
paraformaldehyde for 20 minutes and then thoroughly washed with PBS. The cells were267
permeabilised with 500 µl of 0.1% v/v Triton X-100 solution for 40 minutes. The solution268
was aspirated and the cells were washed with PBS. Blocking of unspecific binding sites as a269
result of epitomes on the cell layers was carried out via the addition of 500 µl of 3% v/v goat270
serum in 1% w/v BSA in PBS for 40 minutes. The blocking solution was removed and 500 µl271
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of anti-OCN primary antibody solution (1:200 dilution in 1% w/v BSA in PBS) was added.272
The scaffolds were incubated at 4°C overnight. After incubation, the antibody solution was273
removed, the scaffolds were washed with PBS and then incubated at room temperature for274
two hours in 500 µl of a 1:200 solution of Alexa Flour 488 goat anti-rabbit secondary IgG, in275
1% w/v BSA in PBS. After incubation, the secondary antibody solution was removed and the276
scaffolds were washed with PBS. In order to stain the DNA of cells, the scaffolds were277
incubated for a further 15 minutes in 1 µg/ml Hoechst dye dissolved in 1% w/v BSA in PBS278
at room temperature. After incubation, the Hoechst dye was removed and the scaffolds were279
thoroughly washed with PBS and then viewed under a dissection microscope. The images of280
PLGA and composite scaffolds were processed and compared using the ImageJ software281
(Version 1.48, National Institute of Health, Bethesda, MD, USA). Four images were taken of282
four different areas on each scaffold and then converted into binary formats so that the283
stained areas could be calculated.284
285
2.15 Statistical Analyses286
A statistical analysis of the data was carried out using Microsoft Excel. An unpaired t test and287
the ANOVA procedure were used and the results were deemed significant when p < 0.05.288
3. Results289
3.1 Physical characterization of PLGA/chitosan composite microspheres and scaffolds290
BSA-encapsulated PLGA/chitosan composite microspheres were formulated using291
TPP as a cross-linker as detailed in section 2.2. Both the PLGA and composite microspheres292
appeared smooth, as shown in the SEM images in Figure 1A and B, respectively. Thus, the293
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addition of chitosan cross-linked with TPP did not alter the superficial appearance of the294
microspheres and no unprocessed, free chitosan is visible from the SEM images. Size295
analysis revealed the average diameters of the PLGA and composite microspheres to be 69.75296
± 21.47 µm and 66.85 ± 22.68 µm, respectively (Figure 1C).297
298
The FTIR spectra of the raw materials and microspheres are presented in Figure 2.299
The chitosan spectrum shows a high-intensity peak at 3400 cm-1, which corresponds to300
stretching vibrations of the O-H and N-H bonds, in addition to hydrogen bonding in the301
backbone (Azevedo et al., 2011). The characteristic peak at 1647 cm-1 is a result of the amide302
functionality and may be present as a consequence of the axial deformation of the C=O bond303
(Azevedo et al., 2011) and strong N-H bending (Misch et al., 1999). Peaks present at 1019304
and 1086 cm-1 (corresponding to C-O stretch vibrations), and 1152 cm-1 (asymmetric stretch305
of the C-O-C bond) are also indicative of chitosan (Azevedo et al., 2011).306
The TPP spectrum, similarly, shows a peak of significant intensity at 3390 cm-1,307
corresponding to the stretching vibrations of the O-H bond. Peaks around the 1095 cm-1308
region are an indication of the P=O phosphate group. The PLGA spectrum presents a peak at309
3473 cm-1, which is indicative of vibration of the terminal O-H groups. Other peaks that310
indicate PLGA are present at 743 cm-1 (C-H bend), 1086 and 1180 cm-1 (C-O stretch), 1381311
cm-1 (C-H bend), 1771 cm-1 (the carbonyl C=O) and 2876 cm-1 (CH2 bend) (Ganji and312
Abdekhodaie, 2010). Both PLGA and PLGA/chitosan composite BSA-loaded microspheres313
show peaks at identical wavelengths, which suggests that the microspheres are predominantly314
PLGA. Moreover, the spectra of PLGA and PLGA/chitosan composite microspheres show315
peaks at 1621 cm-1 and 1639 cm-1, respectively, which are attributed to the C=O bond of the316
amide groups that are found both in BSA and chitosan. However, there does appear to be a317
slightly more pronounced peak at 1639 cm-1 on the spectrum of the PLGA/chitosan318
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composite microspheres, which corresponds to the amide C=O bond suggesting the presence319
of chitosan in the formulation.320
The ToF-SIMS analysis was carried out in order to ascertain the presence of chitosan321
on the scaffold surfaces. BSA-free scaffolds were analysed based on the overlap of chitosan322
and BSA secondary ion peaks (discussed in section 2.6). Intensities of nitrogen-containing323
positive secondary ion peaks CH4N+ (m/z = 30) and C4H5N2+ (m/z = 81), as well as the324
negative ion peak CN- (m/z = 26) were all significantly higher in the composite325
PLGA/chitosan scaffolds when compared to the chitosan-free scaffolds, as shown in Figure326
3A. However, there was no significant difference between the profiles of diagnostic PLGA327
ion peaks for the PLGA and composite scaffolds (Figure 3B).328
The incorporation of chitosan did not elicit a significant change in the encapsulation329
efficiency of BSA in the microspheres, with 80.58 ± 17.06% and 81.57 ± 3.06% of the330
protein being encapsulated into the PLGA and PLGA/chitosan composite microspheres,331
respectively. Moreover, there was no statistical difference in the encapsulation efficiencies of332
the PLGA and composite scaffolds (2.81 mg/g [93.68% ± 3.50%] and 2.52 mg/g [84.02% ±333
12.08%] for the PLGA and PLGA/chitosan composite scaffolds, respectively).334
3.2 Release of BSA from microspheres and scaffolds335
The release profile of BSA was mapped over 28 days from both microspheres and336
scaffolds sintered at 37°C (Figure 4). The initial burst release after 24 hours from the PLGA337
microspheres was significantly higher than from the PLGA/chitosan composite microspheres,338
0.93 ± 0.06 µg/mg and 0.57 ± 0.03 µg/mg, respectively (p < 0.05). After 28 days, 1.72 ± 0.23339
µg/mg of BSA was released from the PLGA microspheres, which was significantly higher in340
comparison to 1.20 ± 0.05 µg/mg from the PLGA/chitosan composite microspheres (p =0.05)341
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Similarly, there was a significant retardation of the initial burst release from the342
scaffolds containing PLGA/chitosan composite microspheres, 0.10 ± 0.02 µg/mg, in343
comparison to the PLGA scaffolds, 0.16 ± 0.01 µg/mg (p < 0.05, Figure 4B).344
345
3.3 Sintering of microspheres into scaffolds346
In order to study the effect of the scaffold preparation method on their subsequent347
morphology and mechanical strength, the PLGA and PLGA/chitosan composite scaffolds348
were prepared using two different methods. Firstly, a paste was formed from the349
microspheres as previously reported (Boukari et al., 2015). In the second method, we aimed350
to study the ability of the microspheres to sinter post-injection through a 19-G needle into a351
scaffold mould. This was then followed by a 17-hour incubation period at 37°C. Photographs352
of the resulting scaffolds and their compressive strengths are presented in Figure 5A and B,353
respectively. The sintering process results in the expulsion of water so that the components354
within close proximity. We believe that this favours ‘fusion’ and bond formation within the355
scaffolds. This approach to scaffold sintering at 37oC is superior to the more harsh methods356
employing elevated temperatures and reagents.357
The overall appearances of PLGA and composite scaffolds were very similar (Figure358
5A). However, when comparing scaffolds prepared using the paste method, the compressive359
strength of PLGA/chitosan composite scaffolds was significantly higher (0.846 ± 0.272 MPa)360
than the PLGA scaffolds (0.406 ± 0.265 MPa, p < 0.05).361
Figure 5A shows that it was possible to successfully sinter a microsphere suspension362
post-injection, thus, forming intact scaffolds that retained their shape when removed from the363
mould. This confirms the injectable potential of the microspheres. When scaffolds were364
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sintered as a suspension post-injection, there was no significant difference between the365
compressive strengths of the PLGA and PLGA/chitosan composite scaffolds, 0.086 ± 0.068366
MPa and 0.048 ± 0.00096 MPa, respectively (p > 0.05, Figure 5B); however, it is likely that367
the compressive values may be below the lower limit of threshold of the machine.368
369
3.4 Cell proliferation on scaffolds370
The culturing of primary hMSCs on the scaffolds was used as a means to test their371
cytocompatibility. Cell proliferation was assessed using the Presto Blue viability reagent on372
day 1, 3, 6 and 8 (Figure 6A).373
Cell proliferation increased over time on both scaffold types. On day 1, the cell374
numbers on PLGA and PLGA/chitosan composite scaffolds were 1.06 × 104 and 1.03 × 104,375
respectively. Both types of scaffolds exhibited a very similar cell growth profile with no376
statistically significant difference found between them (p > 0.05) on day 1, 3 and 6. However,377
the cell number on day 8 was significantly higher on the PLGA scaffolds (p < 0.05) at 6.25 ×378
104 and 4.45 × 104 for PLGA and PLGA/chitosan composite scaffolds, respectively. SEM379
images of the cell-scaffold constructs on day 8 are shown in Figure 6B and C, with cells380
visibly distributed between microspheres in both scaffold types.381
382
3.5 Assessment of mineralization383
The extent of mineralization on the scaffolds after 21 days in culture media was384
assessed using the von Kossa assay as described in section 2.14. Dark brown/black nodules385
(indicated by the white arrow in Figure 7B) are visible on the scaffolds and represent positive386
staining. A qualitative analysis shows that there are more nodules on the PLGA/chitosan387
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composite scaffolds (Figure 7B), which appear darker in the figure, in comparison to the388
PLGA scaffolds (Figure 7A).389
3.6 Osteocalcin immunostaining390
The presence of the bone marker protein, osteocalcin, was detected using the391
immunostaining technique described in section 2.14. The data obtained was processed using392
ImageJ, which allowed us to quantify the amount of stain present on each scaffold. The393
results of this analysis show that there was an increase in osteocalcin staining on the394
composite scaffolds when compared to the PLGA scaffolds (p < 0.05, Figure 8A). When395
osteogenic media was used (data not shown), the osteocalcin staining on the PLGA/chitosan396
and PLGA scaffolds was not significantly different (p > 0.05). Processed, merged images are397
shown in Figure 8B and C, with osteocalcin represented in green, and cell DNA in blue.398
4. Discussion399
Scaffolds made from biodegradable microspheres are a promising approach for bone400
regeneration. However, there are several features to consider when developing such systems.401
These include the incorporation of porosity and growth factors into the scaffolds, whilst at the402
same time providing mechanical strength to enable the microspheres to be injectable and403
sinter in situ. Some research groups have developed scaffolds with some of these properties;404
however, most groups do not take into account all desirable features in one system. In the405
present study, we propose a novel dual-application PLGA/chitosan composite scaffold406
system with the potential to meet all of the above desirable criteria. The system comprises407
porous and non-porous protein-loaded microspheres with the ability to sinter at 37°C and408
release protein. The mechanical strength of the system is dependent upon its mode of409
application, with a higher compressive strength achievable when it is applied as a paste, and410
sufficient strength to maintain the shape (as evident from the fact that the microspheres411
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sintered at 37°C and were subsequently removed from the mould intact) when injected as a412
suspension. The cytocompatibility and osteogenic potential of the formulation were413
evaluated and compared with our previously reported system (Boukari et al., 2015).414
Protein-loaded microspheres were formulated using PLGA and chitosan, where the415
chitosan was cross-linked using TPP. There were no observable differences in the416
morphology and size of the composite microspheres when compared with PLGA417
microspheres. The presence of chitosan within the composite scaffolds formed via the paste418
method was confirmed by ToF-SIMS, suggests that chitosan is formed as part of the419
microstructure of the particles. Furthermore, the composite scaffolds demonstrated higher420
compressive strength than the PLGA scaffolds. In this regard, chitosan contributes to the421
mechanical strength of the scaffolds, due to interactions between the negatively charged422
PLGA (Balmert et al., 2015) and the protonated amine groups in the chitosan structure.423
Moreover, the compressive strength demonstrated by the composite scaffolds fell within an424
acceptable range as reported by Misch et al. (1999).425
The chitosan coating attenuated the initial burst release from the microspheres and426
scaffolds, and this reduction may partly be attributed to chitosan complexing with BSA427
(isoelectric point, approximately 5), thereby, impeding its release. The ability of chitosan, a428
natural polyelectrolyte, to non-covalently bind to negatively charged proteins has been429
reported (Boeris et al., 2010). A similar observation of a reduced burst release was made for430
the same system when encapsulated with lysozyme, which is positively charged at a neutral431
pH (data not shown). This suggests that other factors contribute to the reduction in burst432
release. It has been reported that the burst release of proteins from PLGA microspheres is433
usually due to protein residing near, or on the surface of, the delivery system (Zeng and434
Liang, 2010). We believe that the formation of a chitosan -TPP matrix layer slows the release435
of the protein and significantly contributes to the attenuation in the initial burst release. This436
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effect has been demonstrated in PLGA/chitosan microspheres encapsulated with a non-437
protein drug, rifampicin, in which the addition of chitosan caused a reduction in the burst438
release (Manca et al., 2008). The slower, steadier release of BSA from the microspheres and439
scaffolds containing PLGA/chitosan is desirable in BMP-2 applications. The controlled440
release reduces the need for supra-physiological loadings, which are necessary when there is441
a huge initial loss via a burst release (Kirby et al., 2011).442
The system described herein possesses dual-applicability arising from the443
formulation’s potential of having two application modes (i) a paste that is implanted within a444
degenerated bone tissue, takes the shape of the defect area and then sinters at 37°C, and (ii)445
the injection of the microsphere suspension directly into the defect area. The former would be446
useful in applications requiring a relatively stronger scaffold, such as the regeneration of447
cancellous bone for which the ultimate compressive strength has been reported to range from448
0.22 to 10.44 MPa (Misch et al., 1999). However, the latter is more suited to applications in449
which the delivery system may be injected and remain in one location, hence, allowing the450
controlled delivery of a specific, known dose of protein to the site. To our knowledge, this is451
the first time that the ability of microspheres to sinter at 37°C, post-injection, has been452
demonstrated.453
The ability of cells to attach and grow on the scaffolds is paramount in the454
development of protein delivery systems in regenerative medicine. For this reason, the455
cytocompatibility of the scaffolds with hMSCs was investigated. The cell number increased456
on the composite scaffolds over the 8-day period from 1.03 × 104 on day 1, to 4.45 × 104 on457
day 8. There was no significant difference between cell numbers on the composite and PLGA458
scaffolds, except on day 8, by which time the cell numbers were higher on PLGA scaffolds (p459
< 0.05). Although previous studies have investigated the cytocompatibility of sintered460
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composite PLGA/chitosan microspheres scaffolds with other cell types, these formulations461
were not capable of sintering in situ (Tao et al., 2014).462
The potential of the scaffold material to promote the differentiation of hMSCs is463
another key factor that is crucial for the production of a successful biomaterial. Although the464
presence of BMP-2 has been shown to promote osteogenic differentiation, the intrinsic ability465
of the material itself to promote the process is also of interest. Chitosan has been reported to466
have numerous biomedical properties, including its ability to improve osteogenesis in animal467
bone defect models (Lee et al., 2008). In this study, we investigated the cell response to468
protein-free scaffolds in basal media in order to study the effect of the scaffold material on469
osteogenesis. The presence of a calcified ECM is a reliable way of confirming osteogenesis470
(Declercq et al., 2005). Nodules were observed on both composite and PLGA scaffolds based471
on von Kossa staining, which indicates the presence of calcium. To provide further472
confirmation of the deposition of a calcified matrix, the presence of osteocalcin, a late protein473
marker of osteogenic differentiation, was determined. Its expression is known to rise with an474
increase in mineralization (Stein et al., (1990). The composite scaffolds showed a475
significantly higher degree of osteocalcin staining when compared to the PLGA scaffolds.476
Previous studies have demonstrated the ability of chitosan-containing scaffolds to induce477
differentiation in the presence of osteogenic media (Jiang et al., 2006), which we also478
confirmed (data not shown). However, relatively little evidence has demonstrated this in479
basal growth media. Therefore, these results suggest that the inclusion of chitosan in PLGA480
microspheres enhanced the osteogenic capacity of the resultant scaffolds.481
5. Conclusion482
In this study, a novel, dual-application composite microsphere system was developed483
with the ability to fuse together as a paste, thereby forming an intact scaffold in the body at484
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37°C. Furthermore, the ability of a suspension of the microspheres to sinter post-injection485
was also demonstrated. Composite PLGA/chitosan microspheres were shown to attenuate the486
initial burst release and elicited a steady, slow release of protein over 28 days. The scaffold’s487
cytocompatibility and ability to promote osteogenesis were also demonstrated. This488
technology, therefore, exhibits potential as a scaffold for bone regeneration and is an489
excellent candidate for further in vitro and in vivo testing.490
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